abbv-932
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 15, 2023 (NCT05738850)
Timeline
Indications
Mechanism of action
- Dopamine D3 receptorMODULATOR
DRD3 modulator
- Dopamine D2 receptorMODULATOR
DRD2 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06953934 | Phase 1 | Oct 14, 2025 | AbbVie |
| NCT07220460 | Phase 2 | Sep 30, 2025 | AbbVie |
| NCT07024797 | Phase 1 | Aug 21, 2025 | AbbVie |
| NCT07071532 | Phase 1 | Jul 15, 2025 | AbbVie |
| NCT06846320 | Phase 2 | Apr 29, 2025 | AbbVie |
| NCT06849791 | Phase 1 | Feb 26, 2025 | AbbVie |
| NCT06605599 | Phase 2 | Oct 15, 2024 | AbbVie |
| NCT06300580 | Phase 1 | Aug 21, 2024 | AbbVie |
| NCT06024239 | Phase 1 | Aug 31, 2023 | AbbVie |
| NCT05738850 | Phase 1 | Feb 15, 2023 | AbbVie, Gedeon Richter Ltd. |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 10 | 10 | 2 | 2023 |
| Gedeon Richter Ltd. | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1